The global mycoplasma testing market is expected to reach USD 943.4
million by 2022, at a CAGR of 12.5% from 2017 to 2022.

The major factors driving this market are the increasing growth of
government support for pharmaceutical and biotechnology industries,
rising R&D activities in life sciences research, and rising cell culture
contamination. On the other hand, the growth of this market is hindered
to some extent due to the stringent regulatory framework &
time-consuming approval processes and the high degree of consolidation
which acts as an entry barrier for new companies.

On the basis of products, the mycoplasma testing market is segmented
into kits & reagents, instruments, and services. The kits & reagents
segment is expected to grow at a higher rate during the forecast period.
This is attributed to the frequent purchase of these consumables as
compared to instruments and increasing use of kit-based techniques.

Based on end users, the mycoplasma testing market is segmented into
pharmaceutical and biotechnology companies, academic research
institutes, contract research organizations (CROs), cell banks, and
other end users. In 2017, pharmaceutical and biotechnology companies
segment is expected to command the largest share and is estimated to
grow at the fastest rate as compared to the other segments. This can be
attributed to the increasing R&D investments in the pharmaceutical
industry.

Asia is estimated to be the fastest growing regional segment in the
global mycoplasma testing market during the forecast period.